Mitigate inflation in the long, intermediate and short terms…
Marc Lichtenfeld has studied the markets for more than 22 years. After getting his start on the trading desk at Carlin Equities, he moved over to Avalon Research Group as a senior analyst. Marc was also a senior columnist at Jim Cramer’s TheStreet.
Currently, Marc is the Chief Income Strategist at Wealthy Retirement and The Oxford Club. He is an author, speaker and financial guru to 500,000 readers who receive his publications each week.
His readers include teachers... engineers... sound technicians... real estate investors... financial advisors... business developers... law enforcement officers... people from all walks of life.
Marc’s mission is to help every one of them generate a safe and steady stream of retirement income that never runs out.
Marc’s top-notch research makes him a sought-after media guest. He has appeared on CNBC, Fox Business and Yahoo Finance. A few of his appearances are below…
If you want to feature Marc, please reach out on our contact page.
Marc in the Media
Marc Lichtenfeld Talks About Gary Cohn’s Resignation
Outlet: Fox Business
Date: March 22, 2018
Description: Marc appears on Fox Business’ Mornings With Maria segment to discuss Gary Cohn’s resignation.
Marc Lichtenfeld Discusses America’s Retirement Crisis
Outlet: Bloomberg Radio
Date: March 22, 2018
Description: Marc makes a guest appearance on Bloomberg Radio to discuss America’s retirement crisis.
Marc Lichtenfeld Books
Marc Lichtenfeld’s first book, Get Rich With Dividends: A Proven System for Double-Digit Returns, achieved best-seller status after its release in 2012. Since, the book has gone through 30 printing runs. And in 2016, the Institute for Financial Literacy named it “Book of the Year.”
In early 2018, Marc released his second book, You Don’t Have to Drive an Uber in Retirement: How to Maintain Your Lifestyle without Getting a Job or Cutting Corners, which hit No. 1 on Amazon’s best-seller list.
To learn more about Marc’s books, check out our Best Finance Books.
Articles by Marc Lichtenfeld
Is declining cash flow sinking this biotech giant?
A huge biotech upswing may be in the making…
You can manage your risk and collect impressive upside…
Drug trial results can skyrocket valuations…
Sometimes feel-good stories don’t pan out…
Demand is up, but supply chains are broken…
How do you value a biotech that lacks revenue?
Do you have someone in mind when you invest?
If only we’d held on to our old baseball cards…